<DOC>
	<DOCNO>NCT00412360</DOCNO>
	<brief_summary>This study Phase III , randomize , open-label , multi-center , prospective study single umbilical cord blood ( UCB ) transplantation versus double UCB transplantation pediatric patient hematologic malignancy .</brief_summary>
	<brief_title>Single v Double Umbilical Cord Blood Transplants Children With High Risk Leukemia Myelodysplasia ( BMT CTN 0501 )</brief_title>
	<detailed_description>BACKGROUND : In nearly every large single center registry analysis outcomes UCB transplantation , cell dose identify important factor influence incidence rate hematopoietic recovery , risk transplant-related mortality , probability survival . Pilot data suggest infusion two partially human leukocyte antigen ( HLA ) -matched UCB unit , always augment graft cell dose , safe may improve neutrophil recovery survival . To determine whether infusion two UCB unit enhances survival , multi-center , open-label , randomized trial propose . As adequate single UCB unit identify 80 % pediatric recipient ( contrast le 30 % adult ) , study open pediatric patient . The population restrict patient high-risk hematologic malignancy , common indication UCB transplantation child . DESIGN NARRATIVE : Participants include patient 1 21 year age diagnosis hematological malignancy two partially HLA-matched UCB unit . Units must HLA-matched 3 6 HLA-A B ( intermediate resolution molecular typing ) DRB1 ( high resolution molecular typing ) 4 6 recipient . Two appropriately HLA-matched unit must available one unit deliver pre-cryopreserved , nucleated cell dose least 2.5 x 10^7 per kilogram second unit delivers least 1.5 x 10^7 per kilogram . Patients randomize 14 day prior initiation conditioning . UCB unit ship prior initiation conditioning . The preparative regimen consist follow : - Fludarabine : 25 mg/m2/day IV Days -10 , -9 , -8 . - Total Body Irradiation ( TBI ) : 165 cGy twice daily Days -7 , -6 , -5 , -4 . - Cyclophosphamide : 60 mg/kg/day x 2 Days -3 -2 . - Day 0 day UCB transplant . The Graft-vs-Host-Disease ( GVHD ) prophylaxis regimen mycophenolate mofetil ( MMF ) 15 mg/kg IV BID Day -3 Day + 45 cyclosporine A ( CSA ) maintain level 200-400 ng/mL begin Day -3 . Patients follow least 24 month post-transplant .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Vidarabine Phosphate</mesh_term>
	<criteria>Two partially HLAmatched UCB unit . Units must HLAmatched minimally 4 6 HLAA B ( intermediate resolution molecular typing ) DRB1 ( high resolution molecular typing ) locus patient , unit must HLAmatched 3 6 HLA A , B , DRB1 locus ( use resolution molecular typing indicate ) . Two appropriately HLAmatched unit must available one unit deliver precryopreserved nucleated cell dose least 2.5 x 10^7 per kilogram second unit least 1.5 x 10^7 per kilogram . Acute myelogenous leukemia ( AML ) follow stage : 1 . High risk first complete remission ( CR1 ) , define follow : Having precede myelodysplasia ( MDS ) High risk cytogenetics ( high risk cytogenetics : del ( 5q ) 5 , 7 , abn ( 3q ) , ( 6 ; 9 ) complex karyotype [ least 5 abnormality ] , ) presence high FLT3 ITDAR ( &gt; 0.4 ) Requiring 1 cycle chemotherapy obtain complete remission ( CR ) ; FAB M6 2 . Second great CR 3 . First relapse le 25 % blast bone marrow 4 . Morphologic complete remission incomplete blood count recovery Therapyrelated AML prior malignancy remission least 12 month Acute lymphocytic leukemia ( ALL ) follow stage : 1 . High risk first remission , define one follow condition : Philadelphia chromosomepositive adult lymphoblastic leukemia ( Ph+ ALL ) Mixed lineage leukemia ( MLL ) rearrangement slow early response ( define M2 [ 525 % blast ] M3 [ 25 % blast bone marrow examination Day 14 induction therapy ] ) Hypodiploidy ( less 44 chromosome DNA index le 0.81 ) End induction M3 bone marrow End induction M2 M23 Day 42 Evidence minimal residual disease ( MRD ) . If patient 's high risk criterion MRD , approval protocol chair protocol officer require enrollment . For COG center , MRD great 1 percent flow MRD end extend induction . 2 . High risk second remission , define one follow condition : Philadelphia chromosomepositive adult lymphoblastic leukemia ( Ph+ ALL ) Bone marrow relapse le 36 month induction Tlineage relapse time Very early isolate central nervous system ( CNS ) relapse ( 6 month diagnosis ) Slow reinduction ( M23 Day 28 ) relapse time Evidence minimal residual disease ( MRD ) . If patient 's high risk criterion MRD , approval protocol chair protocol officer require enrollment . For COG center , MRD great 1 percent flow MRD end extend induction . 3 . Any third subsequent CR NK cell lymphoblastic leukemia CR Biphenotypic undifferentiated leukemia CR first relapse must less 25 % blast bone marrow ( BM ) Myelodysplastic syndrome ( MDS ) stage Chronic myelogenous leukemia ( CML ) chronic accelerate phase All patient evidence CNS leukemia must treat CNS CR eligible study . Patients 16 year old old must Karnofsky score least 70 % patient young 16 year old must Lansky score least 70 % . Patients adequate physical function measure : 1 . Cardiac : Left ventricular ejection fraction great 40 % shorten fraction great 26 % 2 . Hepatic : Bilirubin 2.5 mg/dL ; alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) 5 time upper limit normal ( ULN ) 3 . Renal : Serum creatinine within normal range age , serum creatinine outside normal range age , renal function ( creatinine clearance GFR ) great 70 mL/min/1.73 m^2 4 . Pulmonary : Diffusing capacity lung carbon monoxide ( DLCO ) , forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) great 50 % predict value ( correct hemoglobin ) ; unable perform pulmonary function test , O2 saturation great 92 % room air Pregnant ( Î²positive human chorionic gonadotropin [ HCG ] ) breastfeed Evidence HIV infection HIV positive serology Current uncontrolled bacterial , viral , fungal infection ( currently take medication progression clinical symptom ) Autologous transplant le 12 month prior enrollment Prior autologous transplant disease UCB transplant perform Prior allogeneic hematopoietic stem cell transplant Active malignancy one UCB transplant perform within 12 month enrollment Inability receive TBI Requirement supplemental oxygen HLAmatched relate donor able donate</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Double cord blood</keyword>
</DOC>